Gilead Sciences (GILD) PT Raised to $134 at Piper Jaffray on Another 'Beat and Raise'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil tops $100, yields hit 2023 high; Apple down before Ternus' first launch event as CEO
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Gilead Sciences' (GILD) Price Target Bumped to $135 at Deutsche Bank
July 29, 2015 10:13 AM EDTDeutsche Bank maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) and raised its price target to $135.00 (from $125.00). Analyst Robyn Karnauskas characterized Q2 results as "solid" and said HCV discounts don't look bad.
"We are lowering our US HCV revenues while increasing OUS numbers & model WW revs at $18.5B vs.... More
Gilead Sciences (GILD) PT Lifted to $135 at Baird on Strong Earnings Beat
July 29, 2015 6:58 AM EDTBaird analyst Brian Skorney lifted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $135.00 (from $126.00) following earnings beat.
Skorney commented, "Gilead handily beat expectations, across the board, and raised revenue guidance yet again. Interestingly, nothing in Hep C declined... More
Gilead Sciences (GILD) PT Raised to $120 at Oppenheimer on Solid Q2 Beat
July 29, 2015 6:28 AM EDTOppenheimer analyst Wendy Lam reiterated an Outperform rating and boosted her price target on Gilead Sciences (NASDAQ: GILD) to $120.00 (from $86.00) following solid the Q2 beat.
Lam commented, "GILD reported a healthy 2Q15 EPS and product revenues beat ($3.15/$8.13B vs. $2.71/$7.60B consensus) underpinned by... More
Gilead Sciences (GILD) Tops Q2 EPS by 44c
July 28, 2015 4:02 PM EDTGilead Sciences (NASDAQ: GILD) reported Q2 EPS of $3.15, $0.44 better than the analyst estimate of $2.71. Revenue for the quarter came in at $8.24 billion versus the consensus estimate of $7.61 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
... More